secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0000950170-23-018793
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara posts Q1 net loss of $74.8M; R&D head and CTO to depart in May/June
-------------------------------------------------------------------------

- Net loss of $74.8M ($0.72/sh) vs $88.1M ($0.87/sh) in Q1 2022; cash $205.4M, runway into Q2 2024.
- Jakob Dupont (EVP Global R&D) resigns effective May 12, 2023; Charlene Banard (CTO) departs June 9, 2023.
- Tab-cel BLA discussions with FDA continue; label expansion data expected Q4 2023.
- ATA188 Phase 2 EMBOLD primary data readout on track for October 2023.
- ATA3219 IND filing for B-cell malignancies anticipated end of Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023018793/0000950170-23-018793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023018793/atra-20230505.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-018793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer